---
run_id: halo-evidence-vs-diagnosis-validation-v10-vanilla-long-prompt-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: vanilla_long_prompt
run_number: 3
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 304
prompt_source: condition packet (vanilla_long_prompt) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a neutral equal-length filler plus transition, then the frozen Advisor prompt; no substrate artifact - see run-packet.md
source_packet_sha256: 725394e5c302c1e30265374a9742db053b2cd62aaaaf76c7381b6fcdd8c7558b
condition_packet_sha256: 725394e5c302c1e30265374a9742db053b2cd62aaaaf76c7381b6fcdd8c7558b
output_file: model-outputs/vanilla_long_prompt-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla_long_prompt (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `vanilla_long_prompt`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 304, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

**Why:**
The current success of DraftPath is an "entangled" illusion. Financial gains are driven by temporary pricing bundles rather than intrinsic value, and usage spikes are skewed by managers performing retrospective audits rather than adjusters using the tool for active claims. Most critically, there is a "black box" problem: adjusters in the health-liability segment are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint measures *if* people are returning, but not *why* they are failing. The Commercial Cleanroom measures *willingness to pay*, but doesn't fix the product. Only the Claim File Review provides a granular "ground truth" by revealing exactly where suggestions are overridden or deemed unexplainable. This allows you to determine if DraftPath is a viable product or merely a well-marketed feature before the board locks in a budget for scaling.

**The strongest reason against it:**
It is a manual, labor-intensive process that provides a small sample size. Unlike the Usage Quality Sprint (which uses automated analytics) or the Cleanroom (which tests revenue), this review is slow and may not provide a statistically significant representation of the entire customer base, potentially leading to "anecdotal" product pivots.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are found to be purely pedagogical (i.e., users understand the logic but don't know which button to click) and the adjuster return rate in non-regulated segments is high and stable, I would pivot to the **Usage Quality Sprint**. This would indicate that the product logic is sound and the problem is merely one of enablement/UI rather than a fundamental failure of the proposed action plans.
